Konvergentna validacija farmakoekonomskih aspekata terapije benigne hiperplazije prostate u Crnoj Gori

    March 2016 in “ National Repository of Dissertations in Serbia ”
    Vera Dabanović
    TLDR Dutasteride is more cost-effective than finasteride for treating benign prostatic hyperplasia in Montenegro.
    The study evaluated the cost-effectiveness of treatments for benign prostatic hyperplasia in Montenegro, using pharmacoeconomic modeling, cost studies, and interviews. It compared dutasteride and finasteride over a 20-year horizon with a Markov model and Monte Carlo simulation involving 1,000 virtual patients. The findings indicated that dutasteride had a superior cost-effectiveness ratio compared to finasteride, justifying its funding by Montenegro's Health Insurance Fund. This research aimed to guide the Fund in selecting the most economically favorable treatment strategy, improving patient care for this condition in Montenegro.
    Discuss this study in the Community →